Accelerate Diagnostics, Inc (AXDX): רווח נקי למניה (EPS TTM)
Accelerate Diagnostics (AXDX) leads in rapid sepsis diagnostics, reducing therapy selection time to a few hours. The rolling annual EPS trend visualizes profit dynamics, where -2.13 is the current value of the metric. Revenues rely on the sale of reagents and equipment, while the growth strategy is based on partnering with a global distributor to reduce the rate of capital expenditure.
AXDX (Accelerate Diagnostics Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Accelerate Diagnostics (AXDX) minimizes medical risks by providing rapid infection identification systems to optimize antibiotic therapy. Annual net income per share reflects the actual return on a single security, excluding the impact of issuances. By analyzing the TTM earnings per share trend, an investor sees a cash flow stripped of structural noise. This indicator confirms the stability of revenues from reagent sales. Ignoring a downward trend in this metric risks freezing investment capital.
